Rapport Therapeutics Announces That Topline Results From Its Phase 2 Trial Of RAP-219 In Adults With Acute Bipolar Mania Met Primary Endpoint

The trial met the primary and secondary endpoints with statistically significant placebo-adjusted improvements at Week 3 in the YMRS total score (3.1 points; p=0.045) and CGI-BP Severity of Mania score (0.4 points; p=0.024)

RAP-219–treated patients had a 15.4-point mean reduction in YMRS total score from baseline at Week 3

All 11 items measured by the YMRS improved numerically compared to placebo at Week 3, with improvements in irritability, thought content, disruptive-aggressive behavior, and sexual interest reaching nominal significance

RAP-219 was well tolerated; all treatment-emergent adverse events during the treatment period were mild or moderate

Company to host a conference call today at 8:00 a.m. ET